ClinicalTrials.gg
CompletedNCT01807923TRAFFICUpdated Aug 31, 2015Results posted

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

A Phase 3 interventional study of Lumacaftor Plus Ivacaftor Combination and Ivacaftor in Cystic Fibrosis, Homozygous for the F508del CFTR Mutation, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 90 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-08-31.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
559
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
3rd of 20
559 · median 66
Started
2013
with 6 others
Phase 3
10 of 20
none open now
Registered
6th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 3rd largest by enrollment, is one of 7 that started in 2013, is one of 10 in phase 3, and was the 6th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.

Read the detailed description

This was a Phase 3, randomized, double-blind, placebo-controlled, parallel-group multicenter study of orally administered lumacaftor in combination with ivacaftor in participants aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation.

The study included a Screening Period (Day -28 through Day -1), a Treatment Period (Day 1 [first dose of study drug] to Week 24 ± 5 days), and a Safety Follow-up Visit (4 weeks ± 7 days after the Week 24 Visit).

03

Conditions studied

  • Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CF
  • Homozygous for the F508del CFTR mutation
  • (FEV1) greater than or equal to (>=) 40 percent (%) and less than or equal to (=\<) 90% of predicted normal for age, sex, and height
  • Willing to remain on a stable CF medication regimen through Week 24 or, if applicable, the Safety Follow up Visit

Exclusion criteria

Exclusion Criteria:

  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before first dose of study drug
  • History of solid organ or hematological transplantation
  • History of alcohol or drug abuse in the past year
  • Ongoing or prior participation in an drug study (including studies investigating lumacaftor and/or ivacaftor) within 30 days of screening
  • Use of strong inhibitors, moderate inducers or strong inducers of Cytochrome P450 3A () within 14 days before Day 1 of dosing
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
559 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.

    Drug: Placebo

  • Experimental
    LUM 600 mg qd/IVA 250 mg q12h

    LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.

    Drug: Lumacaftor Plus Ivacaftor Combination · Drug: Ivacaftor

  • Experimental
    LUM 400 mg q12h/ IVA 250 mg q12h

    LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.

    Drug: Lumacaftor Plus Ivacaftor Combination

Interventions

  • DrugLumacaftor Plus Ivacaftor Combination

    Drug pages: Lumacaftor · Ivacaftor

    Fixed dose combination tablet

    Also known as: VX-809+VX-770, LUM+IVA

  • Film-coated tablet

    Also known as: VX-770, IVA

  • DrugPlacebo

    Matching placebo tablet

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24

    Absolute change from baseline at Week 24 was assessed as the average treatment effect at Week 16 and at Week 24. FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.

    Time frame: Baseline, Week 16 and 24

Secondary outcomes

  1. Relative Change From Baseline in Percent Predicted FEV1 at Week 24

    Assessed as the average treatment effect at Week 16 and at Week 24. FEV1 and percent predicted FEV1 are defined in Outcome Measure (OM) 1.

    Time frame: Baseline, Week 16 and 24

  2. Absolute Change From Baseline in Body Mass Index (BMI) at Week 24

    BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).

    Time frame: Baseline, Week 24

  3. Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), the scaled score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Baseline, Week 24

  4. Percentage of Participants With Response Based on Percent Predicted FEV1

    A participant was considered as a responder if the participant had \>=5% increase from baseline in average percent predicted FEV1 at Week 16 and at Week 24 (relative change). FEV1 and percent predicted FEV1 are defined in OM 1. A participant with a missing average relative change from baseline in percent predicted FEV1 at Week 16 and at Week 24 was considered as a non-responder.

    Time frame: Week 16 and 24

  5. Number of Pulmonary Exacerbation Events

    The total number of days on study is equal to the Week 24 date or the last dose date (whichever occurred last) minus the first dose date plus 1. The total number of years (48 weeks) on study is equal to the number of days on study divided by 336. Pulmonary exacerbation events per year (48 weeks) are reported.

    Time frame: through Week 24

  6. Absolute Change From Baseline in Weight at Week 24

    Time frame: Baseline, Week 24

  7. Absolute Change From Baseline in BMI-for-age Z-score at Week 24

    Z-Score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is with range from -infinity to + infinity; 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. BMI-for-age z-score was calculated by using Centers for Disease Control and Prevention (CDC) growth charts for the pediatric population.

    Time frame: Baseline, Week 24

  8. Time-to-First Pulmonary Exacerbation

    Time to first pulmonary exacerbation was assessed using Cox Regression. For participants who completed 24 weeks of treatment, participants without a pulmonary exacerbation before treatment completion were considered censored at the time of treatment completion or at the Week 24 Visit (whichever occurred last). For participants who prematurely discontinued study treatment, participants without a pulmonary exacerbation through the Week 24 Visit were considered censored at the time of the Week 24 Visit.

    Time frame: through Week 24

  9. Percentage of Participants With At Least 1 Pulmonary Exacerbation Event

    Time frame: through Week 24

  10. Absolute Change From Baseline in Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score at Week 24

    EQ-5D-3L: participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). The 5 dimensional 3-level systems are converted into a single index utility score. Values for theoretically possible health states are calculated using a regression model and weighted according to the social preferences of the Unites States (US) general population. For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state.

    Time frame: Baseline, Week 24

  11. Absolute Change From Baseline in EQ-5D-3L VAS Score at Week 24

    The EQ-5D-3L VAS records the participant's self-rated health on a vertical, visual analogue scale where the best state a participant can imagine is marked 100 and the worst state a participant can imagine is marked 0, higher scores indicates a better health state.

    Time frame: Baseline, Week 24

  12. Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domain Scores at Week 24

    The TSQM is a 14-item self-administered questionnaire which measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.

    Time frame: Baseline, Week 24

  13. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Treatment-Emergent Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Nonserious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or that was newly developed at or after the initial dosing of study drug to 28 days after the last dose of study drug is considered treatment-emergent.

    Time frame: up to Week 28

  14. Pre-dose Concentration (Ctrough), Average Pre-dose Concentration (Ctrough,Avg), 3 to 6 Hours Post-dose Concentration (C3-6h), and Average 3 to 6 Hours Post-dose Concentration (C3-6h,Avg)

    Ctrough, Ctrough, avg, C3-6h, and C3-6h, avg for lumacaftor, M28 lumacaftor (lumacaftor metabolite), ivacaftor, M1 ivacaftor (ivacaftor metabolite), and M6 ivacaftor (ivacaftor metabolite) were calculated. C3-6h,ave is average of individual 3 to 6 hours post-dose observed concentrations across Day 15, and Weeks 4 and 8 and Ctrough, ave is average of individual pre-dose observed concentrations across Weeks 4, 8, and 16. This outcome was not planned to be assessed in Placebo arm.

    Time frame: For C3-6h: 3 to 6 hours after morning dose on Day 1 and 15, Week 4 and 8; For C3-6h,avg 3 to 6 hours after morning dose on Day 15, Week 4 and 8; For Ctrough and Ctrough,avg: before morning dose on Week 4, 8, and 16

07

Results

Posted Aug 31, 2015

Participant flow

Participant flow — Overall Study
MilestonePlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Started187185187
Completed182179176
Not completed5611
Withdrew: Adverse event212
Withdrew: Withdrawal of consent (not due to ae)032
Withdrew: Physician decision001
Withdrew: Not eligible (genotype)001
Withdrew: Randomized but not treated325

Outcome measures

PrimaryAbsolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24

Absolute change from baseline at Week 24 was assessed as the average treatment effect at Week 16 and at Week 24. FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.

Time frame:
Baseline, Week 16 and 24
Reported as:
Least squares mean · percent predicted of FEV1
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24
percent predicted of FEV1PlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24-0.44 ± 0.5243.59 ± 0.5252.16 ± 0.530
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = <0.0001 · Least squares (ls) mean difference: 4.03 · 95% CI 2.62 to 5.44
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.0003 · Ls mean difference: 2.60 · 95% CI 1.18 to 4.01
SecondaryRelative Change From Baseline in Percent Predicted FEV1 at Week 24

Assessed as the average treatment effect at Week 16 and at Week 24. FEV1 and percent predicted FEV1 are defined in Outcome Measure (OM) 1.

Time frame:
Baseline, Week 16 and 24
Reported as:
Least squares mean · percent change
Relative Change From Baseline in Percent Predicted FEV1 at Week 24
percent changePlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Relative Change From Baseline in Percent Predicted FEV1 at Week 24-0.34 ± 0.9136.39 ± 0.9143.99 ± 0.923
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = <0.0001 · Ls mean difference: 6.73 · 95% CI 4.27 to 9.19
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.0006 · Ls mean difference: 4.33 · 95% CI 1.86 to 6.80
SecondaryAbsolute Change From Baseline in Body Mass Index (BMI) at Week 24

BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kilogram per square meter (kg/m^2)
Absolute Change From Baseline in Body Mass Index (BMI) at Week 24
kilogram per square meter (kg/m^2)PlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Absolute Change From Baseline in Body Mass Index (BMI) at Week 240.19 ± 0.0700.35 ± 0.0700.32 ± 0.071
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = 0.1122 · Ls mean difference: 0.16 · 95% CI -0.04 to 0.35
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.1938 · Ls mean difference: 0.13 · 95% CI -0.07 to 0.32
SecondaryAbsolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), the scaled score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24
units on a scalePlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 241.10 ± 1.1614.98 ± 1.1782.60 ± 1.192
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = 0.0168 (This test is considered nominally significant because a hierarchical procedure was used and was broken prior to this test.) · Ls mean difference: 3.88 · 95% CI 0.70 to 7.05
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.3569 · Ls mean difference: 1.50 · 95% CI -1.69 to 4.69
SecondaryPercentage of Participants With Response Based on Percent Predicted FEV1

A participant was considered as a responder if the participant had \>=5% increase from baseline in average percent predicted FEV1 at Week 16 and at Week 24 (relative change). FEV1 and percent predicted FEV1 are defined in OM 1. A participant with a missing average relative change from baseline in percent predicted FEV1 at Week 16 and at Week 24 was considered as a non-responder.

Time frame:
Week 16 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Response Based on Percent Predicted FEV1
percentage of participantsPlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Percentage of Participants With Response Based on Percent Predicted FEV122.346.436.8
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · Cochran-Mantel-Haenszel · p = <0.0001 (This test is considered nominally significant because a hierarchical procedure was used and was broken prior to this test.) · Odds ratio (or): 2.9378 · 95% CI 1.8786 to 4.5941
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · Cochran-Mantel-Haenszel · p = 0.0023 (This test is considered nominally significant because a hierarchical procedure was used and was broken prior to this test.) · Odds ratio (or): 2.0592 · 95% CI 1.2920 to 3.2819
SecondaryNumber of Pulmonary Exacerbation Events

The total number of days on study is equal to the Week 24 date or the last dose date (whichever occurred last) minus the first dose date plus 1. The total number of years (48 weeks) on study is equal to the number of days on study divided by 336. Pulmonary exacerbation events per year (48 weeks) are reported.

Time frame:
through Week 24
Reported as:
Number · pulmonary exacerbation events per year
Number of Pulmonary Exacerbation Events
pulmonary exacerbation events per yearPlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Number of Pulmonary Exacerbation Events1.070.770.71
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · Negative Binomial Regression · p = 0.0491 · Event rate ratio: 0.7186 · 95% CI 0.5170 to 0.9987
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · Negative Binomial Regression · p = 0.0169 (This test is considered nominally significant because a hierarchical procedure was used and was broken prior to this test.) · Event rate ratio: 0.6643 · 95% CI 0.4749 to 0.9291
SecondaryAbsolute Change From Baseline in Weight at Week 24
Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kilograms (kg)
Absolute Change From Baseline in Weight at Week 24
kilograms (kg)PlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Absolute Change From Baseline in Weight at Week 240.93 ± 0.2021.34 ± 0.2051.23 ± 0.205
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = 0.1565 · Ls mean difference: 0.40 · 95% CI -0.16 to 0.96
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.2992 · Ls mean difference: 0.30 · 95% CI -0.26 to 0.86
SecondaryAbsolute Change From Baseline in BMI-for-age Z-score at Week 24

Z-Score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is with range from -infinity to + infinity; 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. BMI-for-age z-score was calculated by using Centers for Disease Control and Prevention (CDC) growth charts for the pediatric population.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · z-score
Absolute Change From Baseline in BMI-for-age Z-score at Week 24
z-scorePlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Absolute Change From Baseline in BMI-for-age Z-score at Week 240.0153 ± 0.048860.1132 ± 0.050810.0933 ± 0.05431
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = 0.1539 · Ls mean difference: 0.0980 · 95% CI -0.0370 to 0.2330
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.2713 · Ls mean difference: 0.0781 · 95% CI -0.0615 to 0.2176
SecondaryTime-to-First Pulmonary Exacerbation

Time to first pulmonary exacerbation was assessed using Cox Regression. For participants who completed 24 weeks of treatment, participants without a pulmonary exacerbation before treatment completion were considered censored at the time of treatment completion or at the Week 24 Visit (whichever occurred last). For participants who prematurely discontinued study treatment, participants without a pulmonary exacerbation through the Week 24 Visit were considered censored at the time of the Week 24 Visit.

Time frame:
through Week 24
Reported as:
Median · days
Time-to-First Pulmonary Exacerbation
daysPlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Time-to-First Pulmonary ExacerbationNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · Cox Proportional Hazard Regression · p = 0.0396 · Hazard ratio (hr): 0.692
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · Cox Proportional Hazard Regression · p = 0.0385 · Hazard ratio (hr): 0.691
SecondaryPercentage of Participants With At Least 1 Pulmonary Exacerbation Event
Time frame:
through Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With At Least 1 Pulmonary Exacerbation Event
percentage of participantsPlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Percentage of Participants With At Least 1 Pulmonary Exacerbation Event39.730.130.2
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · Cochran-Mantel-Haenszel · p = 0.0552 · Odds ratio (or): 0.6565 · 95% CI 0.4266 to 1.0103
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · Cochran-Mantel-Haenszel · p = 0.0512 · Odds ratio (or): 0.6438 · 95% CI 0.4142 to 1.0005
SecondaryAbsolute Change From Baseline in Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score at Week 24

EQ-5D-3L: participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). The 5 dimensional 3-level systems are converted into a single index utility score. Values for theoretically possible health states are calculated using a regression model and weighted according to the social preferences of the Unites States (US) general population. For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score at Week 24
units on a scalePlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Absolute Change From Baseline in Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score at Week 240.0006 ± 0.007390.0066 ± 0.007460.0100 ± 0.00757
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = 0.5604 · Ls mean difference: 0.0060 · 95% CI -0.0142 to 0.0262
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.3613 · Ls mean difference: 0.0095 · 95% CI -0.0109 to 0.0298
SecondaryAbsolute Change From Baseline in EQ-5D-3L VAS Score at Week 24

The EQ-5D-3L VAS records the participant's self-rated health on a vertical, visual analogue scale where the best state a participant can imagine is marked 100 and the worst state a participant can imagine is marked 0, higher scores indicates a better health state.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in EQ-5D-3L VAS Score at Week 24
units on a scalePlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Absolute Change From Baseline in EQ-5D-3L VAS Score at Week 241.4 ± 1.033.5 ± 1.042.8 ± 1.04
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = 0.1342 · Ls mean difference: 2.1 · 95% CI -0.7 to 4.9
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.3071 · Ls mean difference: 1.4 · 95% CI -1.3 to 4.2
SecondaryAbsolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domain Scores at Week 24

The TSQM is a 14-item self-administered questionnaire which measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domain Scores at Week 24
units on a scalePlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Effectiveness (n = 163, 156, 144)-5.30 ± 1.6430.19 ± 1.6660.50 ± 1.726
Side Effects (n = 162, 154, 143)2.23 ± 1.119-1.94 ± 1.141-2.51 ± 1.179
Convenience (n = 163, 154, 144)4.37 ± 1.5044.98 ± 1.5407.45 ± 1.579
Global Satisfaction (n= 163, 154, 144)-10.49 ± 1.863-5.00 ± 1.906-3.77 ± 1.956
Statistical analysis
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = 0.0160 · Ls mean difference: 5.49 · 95% CI 1.03 to 9.96
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.0126 · Ls mean difference: 5.80 · 95% CI 1.25 to 10.35
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = 0.0074 · Ls mean difference: -4.18 · 95% CI -7.23 to -1.13
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.0029 · Ls mean difference: -4.74 · 95% CI -7.85 to -1.63
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = 0.7721 · Ls mean difference: 0.61 · 95% CI -3.50 to 4.71
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.1472 · Ls mean difference: 3.08 · 95% CI -1.09 to 7.25
  • Placebo vs LUM 600 mg qd/IVA 250 mg q12h · MMRM · p = 0.0345 · Ls mean difference: 5.49 · 95% CI 0.40 to 10.58
  • Placebo vs LUM 400 mg q12h/ IVA 250 mg q12h · MMRM · p = 0.0109 · Ls mean difference: 6.72 · 95% CI 1.55 to 11.89
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Treatment-Emergent Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Nonserious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or that was newly developed at or after the initial dosing of study drug to 28 days after the last dose of study drug is considered treatment-emergent.

Time frame:
up to Week 28
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Treatment-Emergent Adverse Events (SAEs)
participantsPlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Participants With Treatment-Emergent AEs174175174
Participants With Treatment-Emergent SAEs493333
SecondaryPre-dose Concentration (Ctrough), Average Pre-dose Concentration (Ctrough,Avg), 3 to 6 Hours Post-dose Concentration (C3-6h), and Average 3 to 6 Hours Post-dose Concentration (C3-6h,Avg)

Ctrough, Ctrough, avg, C3-6h, and C3-6h, avg for lumacaftor, M28 lumacaftor (lumacaftor metabolite), ivacaftor, M1 ivacaftor (ivacaftor metabolite), and M6 ivacaftor (ivacaftor metabolite) were calculated. C3-6h,ave is average of individual 3 to 6 hours post-dose observed concentrations across Day 15, and Weeks 4 and 8 and Ctrough, ave is average of individual pre-dose observed concentrations across Weeks 4, 8, and 16. This outcome was not planned to be assessed in Placebo arm.

Time frame:
For C3-6h: 3 to 6 hours after morning dose on Day 1 and 15, Week 4 and 8; For C3-6h,avg 3 to 6 hours after morning dose on Day 15, Week 4 and 8; For Ctrough and Ctrough,avg: before morning dose on Week 4, 8, and 16
Reported as:
Mean · microgram per milliliter (mcg/mL)
Pre-dose Concentration (Ctrough), Average Pre-dose Concentration (Ctrough,Avg), 3 to 6 Hours Post-dose Concentration (C3-6h), and Average 3 to 6 Hours Post-dose Concentration (C3-6h,Avg)
microgram per milliliter (mcg/mL)LUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
LUM, Day 1: C3-6h (n = 180, 175)27.5 ± 12.518.4 ± 8.55
LUM, Day 15: Ctrough (n = 172, 175)7.56 ± 5.3314.1 ± 6.99
LUM, Day 15: C3-6 (n = 167, 171)26.1 ± 11.523.6 ± 8.54
LUM, Week 4: Ctrough (n = 172, 178)7.75 ± 5.0513.4 ± 6.70
LUM, Week 4: C3-6 (n = 170, 171)28.4 ± 11.224.2 ± 8.66
LUM, Week 8: Ctrough (n = 173, 174)7.43 ± 5.6013.4 ± 6.68
LUM, Week 8: C3-6 (n = 165, 171)28.2 ± 11.224.4 ± 8.80
LUM, Week 16: Ctrough (n = 165, 164)6.95 ± 4.9913.5 ± 7.49
M-28 LUM, Day 1: C3-6h (n = 180, 175)0.220 ± 0.1070.179 ± 0.0811
M-28 LUM, Day 15: Ctrough (n = 172, 175)1.25 ± 0.6141.48 ± 0.590
M-28 LUM, Day 15: C3-6 (n = 167, 171)1.37 ± 0.6061.49 ± 0.576
M-28 LUM, Week 4: Ctrough (n = 172, 178)1.31 ± 0.6461.48 ± 0.642
M-28 LUM, Week 4: C3-6 (n = 170, 171)1.39 ± 0.6351.49 ± 0.615
M-28 LUM, Week 8: Ctrough (n = 173, 174)1.32 ± 0.6841.53 ± 0.674
M-28 LUM, Week 8: C3-6 (n = 165, 171)1.42 ± 0.6581.56 ± 0.669
M-28 LUM, Week 16: Ctrough (n = 165, 164)1.30 ± 0.7691.57 ± 0.757
IVA, Day 1: C3-6h (n = 180, 175)1.29 ± 0.6241.24 ± 0.630
IVA, Day 15: Ctrough (n = 172, 176)0.151 ± 0.1230.115 ± 0.123
IVA, Day 15: C3-6 (n = 167, 171)0.557 ± 0.3110.413 ± 0.199
IVA, Week 4: Ctrough (n = 172, 178)0.142 ± 0.1070.105 ± 0.083
IVA, Week 4: C3-6 (n = 170, 171)0.638 ± 0.3250.456 ± 0.235
IVA, Week 8: Ctrough (n = 173, 174)0.130 ± 0.1010.0894 ± 0.0726
IVA, Week 8: C3-6 (n = 165, 171)0.648 ± 0.3640.470 ± 0.295
IVA, Week 16: Ctrough (n = 165, 164)0.133 ± 0.1310.0834 ± 0.0622
M-1 IVA, Day 1: C3-6h (n = 180, 175)2.46 ± 1.292.41 ± 1.35
M-1 IVA, Day 15: Ctrough (n = 172, 176)0.665 ± 0.5780.511 ± 0.530
M-1 IVA, Day 15: C3-6 (n = 167, 171)1.94 ± 0.9811.71 ± 0.867
M-1 IVA, Week 4: Ctrough (n = 172, 178)0.628 ± 0.4920.450 ± 0.345
M-1 IVA, Week 4: C3-6 (n = 170, 171)2.21 ± 1.011.76 ± 0.932
M-1 IVA, Week 8: Ctrough (n = 173, 174)0.584 ± 0.4510.404 ± 0.381
M-1 IVA, Week 8: C3-6 (n = 165, 171)2.17 ± 1.061.78 ± 0.975
M-1 IVA, Week 16: Ctrough (n = 165, 164)0.589 ± 0.5190.396 ± 0.319
M-6 IVA, Day 1: C3-6h (n = 180, 175)0.976 ± 0.8770.927 ± 0.875
M-6 IVA, Day 15: Ctrough (n = 172, 176)1.68 ± 1.311.67 ± 1.40
M-6 IVA, Day 15: C3-6 (n = 167, 171)3.03 ± 1.962.87 ± 1.81
M-6 IVA, Week 4: Ctrough (n = 172, 178)1.66 ± 1.361.46 ± 0.938
M-6 IVA, Week 4: C3-6 (n = 170, 171)3.07 ± 1.922.49 ± 1.53
M-6 IVA, Week 8: Ctrough (n = 173, 174)1.52 ± 1.121.31 ± 0.946
M-6 IVA, Week 8: C3-6 (n = 165, 171)2.96 ± 1.862.36 ± 1.57
M-6 IVA, Week 16: Ctrough (n = 165, 164)1.40 ± 1.111.33 ± 1.02
LUM: Ctrough,ave (n = 179, 181)7.49 ± 3.9313.5 ± 5.52
LUM: C3-6h,ave (n = 179, 181)27.7 ± 8.6324.0 ± 7.29
M-28 LUM: Ctrough,ave (n = 179, 181)1.31 ± 0.6281.51 ± 0.614
M-28 LUM: C3-6h,ave (n = 179, 181)1.39 ± 0.5961.51 ± 0.585
IVA: Ctrough,ave (n = 179, 181)0.137 ± 0.07730.0989 ± 0.0644
IVA: C3-6h,ave (n = 179, 181)0.614 ± 0.2710.445 ± 0.193
M1-IVA: Ctrough,ave (n = 179, 181)0.606 ± 0.3500.441 ± 0.293
M1-IVA: C3-6h,ave (n = 179, 181)2.11 ± 0.8171.74 ± 0.726
M6-IVA: Ctrough,ave (n = 179, 181)1.57 ± 0.9921.44 ± 0.861
M6-IVA: C3-6h,ave (n = 179, 181)3.04 ± 1.552.57 ± 1.34

Adverse events

Collected over Up to Week 28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—49/184 (26.6%)173/184 (94%)
LUM 600 mg qd/IVA 250 mg q12h—33/183 (18%)175/183 (95.6%)
LUM 400 mg q12h/ IVA 250 mg q12h—33/182 (18.1%)172/182 (94.5%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventPlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations41/18419/18317/182
HaemoptysisRespiratory, thoracic and mediastinal disorders2/1840/1835/182
Distal intestinal obstruction syndromeGastrointestinal disorders2/1842/1832/182
InfluenzaInfections and infestations1/1842/1830/182
PneumoniaInfections and infestations0/1842/1830/182
CoughRespiratory, thoracic and mediastinal disorders0/1842/1831/182
Implant site thrombosisGeneral disorders0/1842/1830/182
TracheobronchitisInfections and infestations1/1841/1831/182
Kidney infectionInfections and infestations0/1840/1831/182
Urinary tract infectionInfections and infestations0/1840/1831/182
Most frequent other events
Showing 10 of 403
Most frequent other events
EventPlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12h
CoughRespiratory, thoracic and mediastinal disorders66/18452/18347/182
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations58/18457/18354/182
HeadacheNervous system disorders25/18428/18329/182
NasopharyngitisInfections and infestations20/1849/18326/182
HaemoptysisRespiratory, thoracic and mediastinal disorders23/18422/18326/182
Respiration abnormalRespiratory, thoracic and mediastinal disorders9/18426/18314/182
Sputum increasedRespiratory, thoracic and mediastinal disorders23/18415/18325/182
Nasal congestionRespiratory, thoracic and mediastinal disorders25/1849/18311/182
DiarrhoeaGastrointestinal disorders13/18416/18324/182
Oropharyngeal painRespiratory, thoracic and mediastinal disorders10/18424/18311/182

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants who received any amount of study drug.

Age, Continuous
Age, Continuous(years)PlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12hTotal
Mean25.0 ± 10.8024.7 ± 9.7125.5 ± 10.0925.1 ± 10.20
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLUM 600 mg qd/IVA 250 mg q12hLUM 400 mg q12h/ IVA 250 mg q12hTotal
Female848684254
Male1009798295
08

Study locations

90 sites
  • Birmingham, Alabama, United States
  • Anchorage, Alaska, United States
  • Tucson, Arizona, United States
  • Little Rock, Arkansas, United States
  • Fresno, California, United States
  • La Jolla, California, United States
  • Loma Linda, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Madera, California, United States
  • Oakland, California, United States
  • Palo Alto, California, United States
  • Denver, Colorado, United States
  • Gainsville, Florida, United States
  • Hollywood, Florida, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Boise, Idaho, United States
  • Chicago, Illinois, United States
  • Park Ridge, Illinois, United States
  • Peoria, Illinois, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Kansas City, Missouri, United States
  • Bedford, New Hampshire, United States
  • Lebanon, New Hampshire, United States
  • Long Branch, New Jersey, United States
  • Hawthorne, New York, United States
  • New York, New York, United States
  • Valhalla, New York, United States
  • Chapel Hill, North Carolina, United States
  • Durham, North Carolina, United States
  • Akron, Ohio, United States
  • Cincinnati, Ohio, United States
  • Dayton, Ohio, United States
  • Portland, Oregon, United States
  • Hershey, Pennsylvania, United States
  • Knoxville, Tennessee, United States
  • Austin, Texas, United States
  • Tyler, Texas, United States
  • Colchester, Vermont, United States
  • Charlottesville, Virginia, United States
  • Norfolk, Virginia, United States
  • Seattle, Washington, United States
  • Morgantown, West Virginia, United States
  • Madison, Wisconsin, United States
  • Broadmeadow, New South Wales, Australia
  • Westmead, New South Wales, Australia
  • Adelaide, South Australia, Australia
  • Halifax, British Columbia, Canada
  • Vancouver, British Columbia, Canada
  • Ottawa, Ontario, Canada
  • Toronto, Ontario, Canada
  • Brno, Czech Republic
  • Plzen-Bory, Czech Republic
  • Praha 5, Czech Republic
  • Strasbourg Cedex 2, Bas Rhin, France
  • Roscoff, Finistere, France
  • Paris Cedex 14, Paris, France
  • Paris Cedex 15, Paris, France
  • Bron Cedex, Rhone, France
  • Pierre Benite, Rhone, France
  • Tuebingen, Baden Wuerttemberg, Germany
  • Erlangen, Bayern, Germany
  • Wuerzburg, Bayern, Germany
  • Koeln, Nordrhein Westfalen, Germany
  • Leipzig, Sachsen, Germany
  • Berlin, Germany
  • Tallaght, Dublin, Ireland
  • Dublin, Ireland
  • Ancona, Italy
  • Firenze, Italy
  • Genova, Italy
  • Milano, Italy
  • Roma, Italy
  • Verona, Italy
  • Amsterdam, Netherlands
  • Den Haag, Netherlands
  • Nijmegen, Netherlands
  • Rotterdam, Netherlands
  • Goteborg, Sweden
  • Stockholm, Sweden
  • Uppsala, Sweden
  • Exeter, Devon, United Kingdom
  • Southhampton, Hampshire, United Kingdom
  • Nottingham, Nottinghamshire, United Kingdom
  • Birmingham, West Midlands, United Kingdom
  • Belfast, United Kingdom
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗
  • Flume PA, Suthoff ED, Kosinski M, Marigowda G, Quittner AL. Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. J Cyst Fibros. 2019 Sep;18(5):737-742. doi: 10.1016/j.jcf.2018.12.004. Epub 2018 Dec 23. PubMed 30587335 ↗
  • McColley SA, Konstan MW, Ramsey BW, Stuart Elborn J, Boyle MP, Wainwright CE, Waltz D, Vera-Llonch M, Marigowda G, Jiang JG, Rubin JL. Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. J Cyst Fibros. 2019 Jan;18(1):94-101. doi: 10.1016/j.jcf.2018.07.011. Epub 2018 Aug 23. PubMed 30146268 ↗
  • Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda G, Waltz D, Wainwright CE; VX-809 TRAFFIC and TRANSPORT study groups. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med. 2016 Aug;4(8):617-626. doi: 10.1016/S2213-2600(16)30121-7. Epub 2016 Jun 10. PubMed 27298017 ↗
  • Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17. PubMed 25981758 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 4 months after primary completion. A results delay was requested in May 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2013
First posted
Mar 8, 2013
Start
May 2013
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results delay requested
May 8, 2015
Results first posted
Aug 31, 2015
Last update
Aug 31, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01807923
Responsible party
Sponsor
First posted
Mar 8, 2013
Start date
May 2013
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Aug 31, 2015
Last update
Aug 31, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lumacaftor · Ivacaftor

Start the discussion